Adaptimmune Therapeutics plc American Depositary Shares (ADAP)
Company News
Evaxion A/S has appointed Dr. Helen Tayton-Martin as its new CEO, effective November 24, 2025. She brings extensive biotech experience from Adaptimmune and will lead the company's AI-powered vaccine development strategy.
The FDA is expected to make several landmark decisions in Q3, including approvals for treatments for schizophrenia, PTSD, and liver disease. These decisions could be impacted by recent biotechnology acquisitions.
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarter...
The company bulks up its pipeline by regaining the rights to two of its clinical programs.